Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ruby Maharjan"'
Autor:
Ruby Maharjan, Laxman Subedi, Rudra Pangeni, Saurav Kumar Jha, Seo Hee Kang, Kwan-Young Chang, Youngro Byun, Jeong Uk Choi, Jin Woo Park
Publikováno v:
Drug Delivery, Vol 28, Iss 1, Pp 2313-2328 (2021)
In this study, we developed oral pemetrexed (PMX) for metronomic dosing to enhance antitumor immunity. PMX was electrostatically complexed with positively charged lysine-linked deoxycholic acid (DL) as an intestinal permeation enhancer, forming PMX/D
Externí odkaz:
https://doaj.org/article/ae87ec3ea3aa4f77beaa8a3f22a6c13f
Publikováno v:
Journal of Nepal Health Research Council, Vol 18, Iss 4 (2021)
Rituximab is a chimeric monoclonal antibody directed against the CD20 expressed on B cells, originally used to treat lymphoma but is increasingly used for the treatment of autoimmune diseases. Membranous nephropathy is an autoimmune disease resulting
Externí odkaz:
https://doaj.org/article/e3202091033544a19b4dbce69c9a9359
Autor:
Ruby Maharjan, Rudra Pangeni, Saurav Kumar Jha, Jeong Uk Choi, Kwan-Young Chang, Young Kweon Choi, Jin Woo Park, Youngro Byun
Publikováno v:
Pharmaceutics, Vol 11, Iss 7, p 332 (2019)
Metronomic chemotherapy (MCT) is defined as the frequent administration of low-dose chemotherapeutics, without long drug-free periods, with the exertion of antitumor activity exclusively through anti-angiogenic mechanisms. In this study, we have deve
Externí odkaz:
https://doaj.org/article/60f29e8f466340cf8426ba025aeb0cab
Autor:
Syed IA Bukhari, Samuel S Truesdell, Chandreyee Datta, Pritha Choudhury, Keith Q Wu, Jitendra Shrestha, Ruby Maharjan, Ethan Plotsker, Ramzi Elased, Sadia Laisa, Vijeta Bhambhani, Yue Lin, Johannes Kreuzer, Robert Morris, Siang-Boon Koh, Leif W. Ellisen, Wilhelm Haas, Amy Ly, Shobha Vasudevan
Publikováno v:
bioRxiv
Our data previously revealed that chemosurviving cancer cells translate specific genes. Here, we find that the m6A-RNA-methyltransferase, METTL3, increases transiently in chemotherapy-treated breast cancer and leukemic cells in vitro and in vivo. Con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c648e406c889874ee2a350109453e95
https://doi.org/10.1101/2023.05.19.540602
https://doi.org/10.1101/2023.05.19.540602
Publikováno v:
Journal of Nepal Health Research Council. 18:580-587
Rituximab is a chimeric monoclonal antibody directed against the CD20 expressed on B cells, originally used to treat lymphoma but is increasingly used for the treatment of autoimmune diseases. Membranous nephropathy is an autoimmune disease resulting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::205d2735a8677947cf2345227b0bc1a5
https://doi.org/10.33314/jnhrc.v18i4.2481
https://doi.org/10.33314/jnhrc.v18i4.2481
Autor:
Jin Woo Park, Laxman Subedi, Saurav Kumar Jha, Jeong Uk Choi, Ruby Maharjan, Kwan-Young Chang, Seo Hee Kang, Rudra Pangeni, Youngro Byun
Publikováno v:
Drug Delivery, Vol 28, Iss 1, Pp 2313-2328 (2021)
Drug Delivery
article-version (VoR) Version of Record
Drug Delivery
article-version (VoR) Version of Record
In this study, we developed oral pemetrexed (PMX) for metronomic dosing to enhance antitumor immunity. PMX was electrostatically complexed with positively charged lysine-linked deoxycholic acid (DL) as an intestinal permeation enhancer, forming PMX/D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01f736ad450f6c126a936c8725bd4a23
https://doi.org/10.1080/10717544.2021.1995077
https://doi.org/10.1080/10717544.2021.1995077
Autor:
Youngro Byun, Young Kweon Choi, Saurav Kumar Jha, Jeong Uk Choi, Rudra Pangeni, Ruby Maharjan, Kwan-Young Chang, Jin Woo Park
Publikováno v:
International Journal of Nanomedicine
Rudra Pangeni,1,* Saurav Kumar Jha,1,* Ruby Maharjan,2 Jeong Uk Choi,2 Kwan-Young Chang,3 Young Kweon Choi,3 Youngro Byun,4 Jin Woo Park11Department of Pharmacy, College of Pharmacy and Natural Medicine Research Institute, Mokpo National University,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26db169f336ddc66f228ad0e3498b1ae
http://europepmc.org/articles/PMC6690926
http://europepmc.org/articles/PMC6690926
Publikováno v:
Cancer Research. 82:339-339
Introduction: Approved angiogenesis inhibitors generally target certain growth factors or their receptors, which exist in both normal and cancerous cells; this results in suppression of cell-signaling pathways throughout the body and causes adverse e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4435a2fb56f4bc0eb538bde2337b587b
https://doi.org/10.1158/1538-7445.am2022-339
https://doi.org/10.1158/1538-7445.am2022-339
Autor:
Ruby Maharjan, Jeong Uk Choi, Seho Kweon, Rudra Pangeni, Na Kyeong Lee, Seong Jin Park, Kwan-Young Chang, Jin Woo Park, Youngro Byun
Publikováno v:
Biomaterials. 281
In this study, we investigated the immune-modulating effects of a novel metronomic chemotherapy (MCT) featuring combined oral oxaliplatin (OXA) and pemetrexed (PMX) for colon cancer. OXA and PMX were ionically complexed with lysine derivative of deox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9ec33412ba92aab07ecd364c0ee904c
https://pubmed.ncbi.nlm.nih.gov/34974206
https://pubmed.ncbi.nlm.nih.gov/34974206
Autor:
Jeong Uk Choi, Sojung Lee, Dong Soo Lee, Jooho Park, Youngro Byun, Ok-Cheol Jeon, Farzana Alam, Jin Woo Park, Foyez Mahmud, Ruby Maharjan
Publikováno v:
Journal of Controlled Release. 284:160-170
There is a growing interest in preclinical research to consider low-dose metronomic chemotherapy as antiangiogenic cancer treatment. Oral metronomic therapy, in particular, has shown much promise with its ease of daily administration and higher thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a30c2acf6fbae82f114e375bae7e6d75
https://doi.org/10.1016/j.jconrel.2018.06.018
https://doi.org/10.1016/j.jconrel.2018.06.018